{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:00:08Z","timestamp":1785236408706,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1053\/j.semnuclmed.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:46:20Z","timestamp":1721177180000},"page":"513-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine?"],"prefix":"10.1053","volume":"54","author":[{"given":"Richard L.","family":"Wahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.semnuclmed.2024.06.002_bib0001","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/j.semnuclmed.2022.12.006","article-title":"Radioimmunotherapy of Non-Hodgkin B-cell lymphoma: An update","volume":"53","author":"Cicone","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.06.002_bib0002","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3109\/10428194.2011.570396","article-title":"Treatment recommendations for radioimmunotherapy in follicular lymphoma: A consensus conference report","volume":"52","author":"Witzig","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.06.002_bib0003","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN guidelines(R) insights: B-Cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.06.002_bib0004","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized radioimmunotherapy for locally advanced non-small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.semnuclmed.2024.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1053\/j.semnuclmed.2024.06.002_bib0006","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.06.002_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.06.002_bib0008","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.semnuclmed.2024.06.002_bib0009","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2024.06.002_bib0010","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","article-title":"TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (LISO-CEL) in patients (PTS) with relapsed\/refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Morschhauser","year":"2023","journal-title":"Hematol Oncol."},{"key":"10.1053\/j.semnuclmed.2024.06.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-Cell Non-Hodgkin lymphomas: Extended follow-up of a phase I\/II study","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.06.002_bib0012","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.06.002_bib0013","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2024.06.002_bib0014","first-page":"6","article-title":"Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice","volume":"3","author":"Sengsayadeth","year":"2021","journal-title":"EJHaem"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.06.002_bib0015","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell-Engaging antibody, in relapsed or refractory large B-Cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.semnuclmed.2024.06.002_bib0016","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-Cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.06.002_bib0017","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.06.002_bib0018","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1148\/78.4.553","article-title":"The radical radiotherapy of regionally localized Hodgkin's disease","volume":"78","author":"Kaplan","year":"1962","journal-title":"Radiology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.06.002_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/172460088700200107","article-title":"Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies","volume":"2","author":"DeNardo","year":"1987","journal-title":"Int J Biol Markers"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.06.002_bib0020","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","article-title":"Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma","volume":"10","author":"Kaminski","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.06.002_bib0021","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000417787","article-title":"High-dose radioimmunotherapy of B cell lymphomas","volume":"24","author":"Press","year":"1990","journal-title":"Front Radiat Ther Oncol"},{"issue":"8 Suppl","key":"10.1053\/j.semnuclmed.2024.06.002_bib0022","first-page":"14S","article-title":"Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation","volume":"39","author":"Wahl","year":"1998","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.06.002_bib0023","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.06.002_bib0024","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2967\/jnumed.115.156190","article-title":"Observational retrospective study of altered biodistribution of tositumomab and 131I-Tositumomab","volume":"56","author":"Wahl","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.06.002_bib0026","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP Plus (131)I-Tositumomab: Long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.06.002_bib0027","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S2352-3026(18)30001-2","article-title":"R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): A single-arm, phase 2, multicentre study","volume":"5","author":"Barr","year":"2018","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1053\/j.semnuclmed.2024.06.002_bib0028","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood-2008-11-188896","article-title":"A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody\/radioantibody therapy","volume":"113","author":"Sharkey","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.06.002_bib0029","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","article-title":"Phase 1\/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy","volume":"113","author":"Illidge","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.semnuclmed.2024.06.002_bib0030","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1182\/blood-2009-03-208918","article-title":"When is a predose a dose too much?","volume":"113","author":"Illidge","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.06.002_bib0031","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","article-title":"Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: Impact of preloading with unlabelled rituximab","volume":"42","author":"Muylle","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.06.002_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112828","article-title":"Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the In-111 ((111)In)\/yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin((R))) theranostic pair in patients with lymphoma at myeloablative dose levels","volume":"13","author":"Wahl","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.06.002_bib0033","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MNM.0000000000000501","article-title":"Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed\/refractory non-Hodgkin's lymphoma","volume":"37","author":"Yadav","year":"2016","journal-title":"Nucl Med Commun"},{"issue":"31","key":"10.1053\/j.semnuclmed.2024.06.002_bib0034","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1200\/JCO.2005.01.0892","article-title":"Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab","volume":"23","author":"Kaminski","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.06.002_bib0035","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2967\/jnumed.117.203299","article-title":"Evaluation of next-generation Anti-CD20 antibodies labeled with (89)Zr in human lymphoma xenografts","volume":"59","author":"Yoon","year":"2018","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.06.002_bib0036","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2967\/jnumed.122.264816","article-title":"Cure of disseminated human lymphoma with [(177)Lu]Lu-ofatumumab in a preclinical model","volume":"64","author":"Shim","year":"2023","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.06.002_bib0037","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.06.002_bib0038","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2967\/jnumed.122.263962","article-title":"Cure of micrometastatic B-Cell lymphoma in a SCID mouse model using (213)Bi-Anti-CD20 monoclonal antibody","volume":"64","author":"Havlena","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.06.002_bib0039","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2967\/jnumed.122.265167","article-title":"Cure of disseminated human lymphoma with [(225)Ac]Ac-ofatumumab in a preclinical model","volume":"64","author":"Longtine","year":"2023","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.06.002_bib0040","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2967\/jnumed.122.264979","article-title":"Evaluation of candidate theranostics for (227)Th\/(89)Zr paired radioimmunotherapy of lymphoma","volume":"64","author":"Abou","year":"2023","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.06.002_bib0041","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","article-title":"Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice","volume":"48","author":"Jacene","year":"2007","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.06.002_bib0042","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2967\/jnumed.110.079947","article-title":"Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab","volume":"51","author":"Baechler","year":"2010","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.06.002_bib0043","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.06.002_bib0044","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.23.01912","article-title":"Long-term follow-up of the RESORT study (E4402): A randomized phase III comparison of two different rituximab dosing strategies for low-tumor burden follicular lymphoma","volume":"42","author":"Kahl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.06.002_bib0045","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2967\/jnumed.109.073155","article-title":"Radioimmunotherapy in non-Hodgkin lymphoma: Opinions of U.S. medical oncologists and hematologists","volume":"51","author":"Schaefer","year":"2010","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.06.002_bib0046","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.06.002_bib0047","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3109\/10428194.2014.894190","article-title":"Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma","volume":"55","author":"Olney","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1053\/j.semnuclmed.2024.06.002_bib0048","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2009.26.8748","article-title":"Radioimmunotherapy of lymphoma: A treatment approach ahead of its time or past its sell-by date?","volume":"28","author":"Illidge","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T10:01:48Z","timestamp":1722679308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299824000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0001299824000552"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.06.002","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}